Neosporin for COVID-19

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Yale University, New Haven, CT
COVID-19+1 More
Neosporin - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The primary objective of this study is to determine whether intranasal application of aminoglycoside (Neosporin) increases local nasal innate immune responses compared to placebo control in healthy participants.

Eligible Conditions

  • COVID-19
  • Coronavirus Disease 2019 (COVID‑19)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: From baseline up to Month 1

Day 8
Change in RNA expression profile of ISGs using single cell RNAseq assay
Day 1and Day 8
Change in RNA expression profile of ISGs using RNAseq assay
Month 1
Change in in interferon response gene expression profile from nasal samples collected measured by RT-PCR
Change in in interferon response profile from nasal samples collected measured by a multiplex ELISA assay

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Neosporin
1 of 2
Vaseline or equivalent
1 of 2
Experimental Treatment
Non-Treatment Group

46 Total Participants · 2 Treatment Groups

Primary Treatment: Neosporin · Has Placebo Group · Phase 1

Neosporin
Drug
Experimental Group · 1 Intervention: Neosporin · Intervention Types: Drug
Vaseline or equivalent
Other
PlaceboComparator Group · 1 Intervention: Vaseline · Intervention Types: Other

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline up to month 1
Closest Location: Yale University · New Haven, CT
Photo of Yale University New Haven  1Photo of Yale University New Haven  2Photo of Yale University New Haven  3
1992First Recorded Clinical Trial
11 TrialsResearching COVID-19
474 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.